Bristol Myers Squibb (CELG-RI) Assets (2009 - 2026)

Bristol Myers Squibb has disclosed Assets across 18 years of filings, most recently posting $86.5 billion for Q1 2026.

• In Q1 2026, Assets fell 6.44% year-over-year to $86.5 billion; the TTM figure through Mar 2026 stood at $86.5 billion (down 6.44% YoY), while the FY2025 annual figure was $90.0 billion, down 2.77% from the prior year.
• Assets slipped to $86.5 billion in Q1 2026, from $90.0 billion in the prior quarter.
• Over the last five years, Assets for CELG-RI reached as high as $103.0 billion in Q1 2022 and fell as low as $86.5 billion in Q1 2026.
• The 5-year median for Assets is $94.6 billion (2024), against an average of $94.9 billion.
• Annual changes were most pronounced in 2022 — Assets dropped 11.45% — and 2024, when it gained 5.04%.
• A 5-year view of Assets shows it stood at $96.8 billion in 2022, then declined by 1.72% to $95.2 billion in 2023, then declined by 2.69% to $92.6 billion in 2024, then dropped by 2.77% to $90.0 billion in 2025, then decreased by 3.96% to $86.5 billion in 2026.
• According to Business Quant data, Assets over the past three periods registered $86.5 billion, $90.0 billion, and $96.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.